BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, Van Beers BE. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging. 2017;45:646-659. [PMID: 27862590 DOI: 10.1002/jmri.25518] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Caparroz C, Forner A, Rimola J, Darnell A, García-Criado Á, Ayuso JR, Reig M, Bruix J, Ayuso C. Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR. Radiol Oncol 2022. [PMID: 35776837 DOI: 10.2478/raon-2022-0024] [Reference Citation Analysis]
2 Aslan S, Eryuruk U, Tasdemir MN, Cakir IM. Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS. Abdom Radiol (NY) 2022. [PMID: 35672474 DOI: 10.1007/s00261-022-03557-7] [Reference Citation Analysis]
3 Okubo H, Atsukawa M, Okubo T, Ando H, Nakadera E, Ikejima K, Nagahara A. Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment. Sci Rep 2022;12:7847. [PMID: 35552472 DOI: 10.1038/s41598-022-11707-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bastati N, Beer L, Ba-Ssalamah A, Poetter-Lang S, Ambros R, Kristic A, Lauber D, Pomej K, Binter T, Simbrunner B, Semmler G, Balcar L, Bican Y, Hodge JC, Wrba T, Trauner M, Reiberger T, Mandorfer M. Gadoxetic Acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and Spleen Diameter Predict Outcomes in ACLD. J Hepatol 2022:S0168-8278(22)00268-9. [PMID: 35525337 DOI: 10.1016/j.jhep.2022.04.032] [Reference Citation Analysis]
5 Pastor CM, Joly F, Vilgrain V, Millet P. Concentrations and pharmacokinetic parameters of MRI and SPECT hepatobiliary agents in rat liver compartments. Eur Radiol Exp 2021;5:42. [PMID: 34545428 DOI: 10.1186/s41747-021-00236-y] [Reference Citation Analysis]
6 Beer L, Bastati N, Ba-Ssalamah A, Pötter-Lang S, Lampichler K, Bican Y, Lauber D, Hodge J, Binter T, Pomej K, Simbrunner B, Semmler G, Trauner M, Mandorfer M, Reiberger T. MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. Liver Int 2020;40:2797-807. [PMID: 32816394 DOI: 10.1111/liv.14648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
7 Li J, Cao B, Bi X, Chen W, Wang L, Du Z, Zhang X, Yu X. Evaluation of liver function in patients with chronic hepatitis B using Gd-EOB-DTPA-enhanced T1 mapping at different acquisition time points: a feasibility study. Radiol Med 2021;126:1149-58. [PMID: 34105102 DOI: 10.1007/s11547-021-01382-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Stinnett G, Taheri N, Villanova J, Bohloul A, Guo X, Esposito EP, Xiao Z, Stueber D, Avendano C, Decuzzi P, Pautler RG, Colvin VL. 2D Gadolinium Oxide Nanoplates as T1 Magnetic Resonance Imaging Contrast Agents. Adv Healthc Mater 2021;10:e2001780. [PMID: 33882196 DOI: 10.1002/adhm.202001780] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
9 Arutyunyants DE, Khovrin VV, Galyan TN, Kulichkin AS, Tarba NS, Filin AV, Metelin AV. [Magnetic resonance imaging in liver function analysis. Modern objective reality]. Khirurgiia (Mosk) 2021;:89-94. [PMID: 34032794 DOI: 10.17116/hirurgia202106289] [Reference Citation Analysis]
10 Bi XJ, Zhang XQ, Zhang T, Xu L, Huang AN, Liu MT, Jiang JF, Chen WB. Quantitative assessment of liver function with hepatocyte fraction: Comparison with T1 relaxation-based indices. Eur J Radiol 2021;141:109779. [PMID: 34029932 DOI: 10.1016/j.ejrad.2021.109779] [Reference Citation Analysis]
11 Lee HJ, Hong SB, Lee NK, Kim S, Seo HI, Kim DU, Han SY, Choo KS. Validation of functional liver imaging scores (FLIS) derived from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Child-Pugh score and FLIS. Eur Radiol 2021. [PMID: 33881570 DOI: 10.1007/s00330-021-07955-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Taouli B, Alves FC. Imaging biomarkers of diffuse liver disease: current status. Abdom Radiol (NY) 2020;45:3381-5. [PMID: 32583139 DOI: 10.1007/s00261-020-02619-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Poetter-Lang S, Bastati N, Messner A, Kristic A, Herold A, Hodge JC, Ba-Ssalamah A. Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 2020;45:3532-44. [PMID: 33034671 DOI: 10.1007/s00261-020-02779-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
15 Ronot M, Leporq B, Van Beers BE, Vilgrain V. CT and MR perfusion techniques to assess diffuse liver disease. Abdom Radiol (NY) 2020;45:3496-506. [PMID: 31768595 DOI: 10.1007/s00261-019-02338-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Leao Filho H, de Oliveira CV, Horvat N. Other types of diffuse liver disease: is there a way to do it? Abdom Radiol (NY) 2020;45:3425-43. [PMID: 32306241 DOI: 10.1007/s00261-020-02530-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Vietti Violi N, Argiriadi P, Rosen A, Cherny M, Weiss A, Hernandez-Meza G, Babb JS, Kihira S, Lewis S, Taouli B. Gadoxetate disodium-enhanced MRI: Assessment of arterial phase artifacts and hepatobiliary uptake in a large series. Eur J Radiol 2020;132:109313. [PMID: 33053495 DOI: 10.1016/j.ejrad.2020.109313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Amorim VB, Parente DB, Paiva FF, Oliveira Neto JA, Miranda AA, Moreira CC, Fernandes FF, Campos CFF, Leite NC, Perez RM, Rodrigues RS. Can gadoxetic acid–enhanced magnetic resonance imaging be used to avoid liver biopsy in patients with nonalcoholic fatty liver disease? World J Hepatol 2020; 12(9): 661-671 [PMID: 33033571 DOI: 10.4254/wjh.v12.i9.661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Tomassini F, Giglio MC, De Simone G, Montalti R, Troisi RI. Hepatic function assessment to predict post-hepatectomy liver failure: what can we trust? A systematic review. Updates Surg 2020;72:925-38. [PMID: 32749596 DOI: 10.1007/s13304-020-00859-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Verde F, Romeo V, Maurea S. Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment. Quant Imaging Med Surg 2020;10:805-7. [PMID: 32269940 DOI: 10.21037/qims.2020.02.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Simeth J, Cao Y. GAN and dual-input two-compartment model-based training of a neural network for robust quantification of contrast uptake rate in gadoxetic acid-enhanced MRI. Med Phys 2020;47:1702-12. [PMID: 31997391 DOI: 10.1002/mp.14055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Bastati N, Beer L, Mandorfer M, Poetter-lang S, Tamandl D, Bican Y, Elmer MC, Einspieler H, Semmler G, Simbrunner B, Weber M, Hodge JC, Vernuccio F, Sirlin C, Reiberger T, Ba-ssalamah A. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid–enhanced MRI Predict Outcomes in Chronic Liver Disease? Radiology 2020;294:98-107. [DOI: 10.1148/radiol.2019190734] [Cited by in Crossref: 14] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
23 Greiser J, Weigand W, Freesmeyer M. Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver. Pharmaceuticals (Basel) 2019;12:E137. [PMID: 31527492 DOI: 10.3390/ph12030137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Matoori S, Froehlich JM, Breitenstein S, Pozdniakova V, Reischauer C, Kolokythas O, Koh D, Gutzeit A. Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement. Eur Radiol 2019;29:5813-22. [DOI: 10.1007/s00330-019-06179-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
25 Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Stoyanova DP, Elmer MC, Semmler G, Simbrunner B, Hodge JC, Sirlin CB, Reiberger T, Ba-Ssalamah A. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 2019;29:6600-10. [PMID: 31001679 DOI: 10.1007/s00330-019-06182-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
26 Kim JE, Kim HO, Bae K, Choi DS, Nickel D. T1 mapping for liver function evaluation in gadoxetic acid–enhanced MR imaging: comparison of look-locker inversion recovery and B1 inhomogeneity–corrected variable flip angle method. Eur Radiol 2019;29:3584-94. [DOI: 10.1007/s00330-018-5947-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
27 Khouri Chalouhi C, Vernuccio F, Rini F, Duca P, Tuscano B, Brancatelli G, Vanzulli A. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine. Eur Radiol 2019;29:3090-9. [PMID: 30547205 DOI: 10.1007/s00330-018-5884-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
28 Sibinga Mulder BG, Visser K, Feshtali S, Vahrmeijer AL, Swijnenburg RJ, Hartgrink HH, van den Boom R, Burgmans MC, Mieog JSD. Gadoxetic acid-enhanced magnetic resonance imaging significantly influences the clinical course in patients with colorectal liver metastases. BMC Med Imaging 2018;18:44. [PMID: 30442100 DOI: 10.1186/s12880-018-0289-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yacoub JH, Elsayes KM, Fowler KJ, Hecht EM, Mitchell DG, Santillan C, Szklaruk J. Pitfalls in liver MRI: Technical approach to avoiding misdiagnosis and improving image quality: Pitfalls in Liver MRI: Technical Approach. J Magn Reson Imaging 2019;49:41-58. [DOI: 10.1002/jmri.26343] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
30 Asenbaum U, Kaczirek K, Ba-Ssalamah A, Ringl H, Schwarz C, Waneck F, Fitschek F, Loewe C, Nolz R. Post-hepatectomy liver failure after major hepatic surgery: not only size matters. Eur Radiol. 2018;28:4748-4756. [PMID: 29767320 DOI: 10.1007/s00330-018-5487-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
31 Besa C, Wagner M, Lo G, Gordic S, Chatterji M, Kennedy P, Stueck A, Thung S, Babb J, Smith A, Taouli B. Detection of liver fibrosis using qualitative and quantitative MR elastography compared to liver surface nodularity measurement, gadoxetic acid uptake, and serum markers. J Magn Reson Imaging 2018;47:1552-61. [PMID: 29193508 DOI: 10.1002/jmri.25911] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
32 Berzigotti A, França M, Martí-aguado D, Martí-bonmatí L. Cuantificación de la fibrosis hepática mediante biomarcadores de imagen. Radiología 2018;60:74-84. [DOI: 10.1016/j.rx.2017.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Leporq B, Lambert S, Ronot M, Vilgrain V, Van Beers B. Simultaneous MR quantification of hepatic fat content, fatty acid composition, transverse relaxation time and magnetic susceptibility for the diagnosis of non-alcoholic steatohepatitis. NMR in Biomedicine 2017;30:e3766. [DOI: 10.1002/nbm.3766] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
34 Giraudeau C, Leporq B, Doblas S, Lagadec M, Pastor CM, Daire JL, Van Beers BE. Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis. Eur Radiol 2017;27:1804-11. [PMID: 27553933 DOI: 10.1007/s00330-016-4536-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]